Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes

References

• Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: areview of current evidence. Diabetologia. 2019;62:3–16.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Li Y, Wang J. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–1523.
   PubMed Web of Science ®Google Scholar
• Egede LE, Hull BJ, Williams JS. “Infections associated with diabetes. Chapter 30” In: Diabetes in America, 3rd. Bethesda, MD: National Institutes of Health; 2017. p. 30.1–30.25. (NIH publ. no. 17-1468).
   Google Scholar
• Young F, Wotton CJ, Critchley JA, et al. Increased risk of tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. J Epidemiol Community Health. 2012;66:519–523.
   PubMed Web of Science ®Google Scholar
• Humphers J, Shibuya N, Fluhman BL, et al. The impact of glycosylated hemoglobin and diabetes mellitus on postoperative wound healing complications and infection following foot and ankle surgery. J Am Podiatr Med Assoc. 2014 June 24. [ [Epub ahead of print]]. DOI:10.7547/13-026.1.
   Web of Science ®Google Scholar
• Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31:1541–1545.
   PubMed Web of Science ®Google Scholar
• Harding GK, Zhanel GG, Nicolle LE, et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med. 2002;347:1576–1583.
   PubMed Web of Science ®Google Scholar
• Harding JL, Benoit SR, Gregg EW, et al. Pavkov, and Leigh Perreault trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000-2015. Diabetes Care. 2019 Oct 15;pii: dc190653. DOI:10.2337/dc19-0653.
   Web of Science ®Google Scholar
• Tseng CP, Wu HS, Wu TH, et al. Clinical characteristics and outcome of patients with community-onset Klebsiella pneumoniae bacteremia requiring intensive care. J Microbiol Immunol Infect. 2013;46:217e23.
   Google Scholar
• Lin YT, Wang FD, Wu PF, et al. Klebsiella pneumoniae liver abscess in diabetic patients: association of glycemic control with the clinical characteristics. BMC Infect Dis. 2013;13:56.
   PubMed Web of Science ®Google Scholar
• Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev. 2016;80:629–661.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF diabetes atlas. 9th; 2019. [cited 2018]. http://www.diabetesatlas.org
   Google Scholar
• Tan YK, Khoo KL, Chin SP, et al. Aetiology and outcome of severe community-acquired pneumonia in Singapore. Eur Respir J. 1998;12:113–115.
   PubMed Web of Science ®Google Scholar
• China Antimicrobial Surveillance Network. Distribution of main strains of 76333 respiratory specimen isolates (CHINET 2017). [cited April 22, 2018]. http://www.chinets.com/Data/AntibioticDrugFast
   Google Scholar
• Baker EH, Baines DL. Airway glucose homeostasis: a new target in the prevention and treatment of pulmonary infection. Chest. 2018;1(53):507–514.
   Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994.
   PubMed Web of Science ®Google Scholar
• Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Emerging role of dipeptidyl peptidase-4 inhibitorsin the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4:753–768.
   PubMedGoogle Scholar
• Kawasaki T, Chen W, Htwe YM, et al. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2018;315:L834–L845.
   PubMed Web of Science ®Google Scholar
• Nieto-Fontarigo JJ, González-Barcala FJ, San-José ME, et al. Expansion of a CD26 low effector TH subset and reduction in circulating levels of sCD26 in stable allergic asthma in adults. J Investig Allergol Clin Immunol. 2018;28:113–125.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S. Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4:257–267.
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Hundborg HH, Lervang HH, et al. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, populationbased study among adults. Clin Infect Dis. 2005;40:628–631.
   PubMed Web of Science ®Google Scholar
• Delamire M, Maugendre D, Moreno M, et al. Impaired leucocyte function in diabetic patients. Diabet Med. 1997;14:29–34.
   PubMed Web of Science ®Google Scholar
• Chen SC, Lee YT, Lai KC, et al. Risk factors for developing metastatic infection from pyogenic liver abscesses. Swiss Med Wkly. 2006;136:119–126.
   PubMed Web of Science ®Google Scholar
• Lin YC, Lu MC, Tang HL, et al. Assessment of hypermucoviscosity as a virulence factor for experimental Klebsiella pneumoniae infections: comparative virulence analysis with hypermucoviscosity-negative strain. BMC Microbiol. 2011;11:50.
   PubMed Web of Science ®Google Scholar
• Lin JC, Siu LK, Fung CP, et al. Impaired phagocytosis of capsular serotype K1 or K2 Klebsiella pneumoniae in type 2 diabetic mellitus patients with poor glycemic control. J Clin Endocrinol Metab. 2006;91:3084–3087.
   PubMed Web of Science ®Google Scholar
• Liu B, Yi H, Fang J, et al. Antimicrobial resistance and risk factors for mortality of pneumonia caused by Klebsiella pneumoniae among diabetics: a retrospective study conducted in Shanghai, China. Infect Drug Resist. 2019;12:1089–1098.
   PubMed Web of Science ®Google Scholar
• Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC Pulm Med. 2019;19:179.
   PubMed Web of Science ®Google Scholar
• Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011;34:369–374.
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017;114:E3119–E3128.
   PubMed Web of Science ®Google Scholar
• Ploquin MJ, Casrouge A, Madec Y, et al. Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage. J Int AIDS Soc. 2018;21:e25144.
   PubMed Web of Science ®Google Scholar
• Chen HH, Lin CL, Yeh SY, et al. Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes. QJM. 2016;109:91–95.
   PubMed Web of Science ®Google Scholar
• Blauenfeldt T, Petrone L, Del Nonno F, et al. Interplay of DDP4 and IP-10 as a potential mechanism for cell recruitment to tuberculosis lesions. Front Immunol. 2018;9:1456.
   PubMed Web of Science ®Google Scholar
• Neuhaus M, Munder A, Schipke J, et al. Lung infection caused by Pseudomonas aeruginosa in a CD26/DPP4 deficient F344 rat model. Inflamm Res. 2019;68:529–544.
   PubMed Web of Science ®Google Scholar
• Gallacher SJ, Thomson G, Fraser WD, et al. Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med. 1995;12:916–920.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Lambertz AM, McCray PB Jr. Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the middle east respiratory syndrome. Am J Pathol. 2016;186:78–86.
   PubMed Web of Science ®Google Scholar
• Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1–21.
   PubMed Web of Science ®Google Scholar
• Jungraithmayr W, DeMeester I, Matheeussen V, et al. Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: the pivotal role of vasoactive intestinal peptide. Peptides. 2010;31:585–591.
   PubMed Web of Science ®Google Scholar
• Tagaya Y, Okada S, Hisada T, et al. Interstitial pneumonia during administration of dipeptidyl peptidase‐4 inhibitors. J Diabetes. 2016;8:442.
   PubMed Web of Science ®Google Scholar
• Sada KE, Wada J, Morinaga H, et al. Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor. Clin Kidney J. 2014;7:182–185.
   PubMedGoogle Scholar
• Tanaka Y, Soda H, Fukuda Y, et al. Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation. Thorac Cancer. 2020;11:470–474.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tada Y, Gladson S, et al. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition. Respir Res. 2017;18(1):177.
   PubMed Web of Science ®Google Scholar
• Engel SS, Round E, Golm GT, et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther. 2013;4(1):119–145. DOI:10.1007/s13300-013-0024-0 PMID: 23700194.
   PubMed Web of Science ®Google Scholar
• Wvan der Zanden R, de Vries F, Lalmohamed A, et al. Use of Dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: a population-based Cohort stud. PLoS One. 2015 Oct 15;10(10):e0139367. DOI:10.1371/journal.pone.0139367 eCollection 2015.
   PubMed Web of Science ®Google Scholar